Tolimidone

产品说明书

Print
Chemical Structure| 41964-07-2 同义名 : MLR-1023;CP 26,154;NSC 314335;CP-26154
CAS号 : 41964-07-2
货号 : A276526
分子式 : C11H10N2O2
纯度 : 99%
分子量 : 202.209
MDL号 : MFCD00866900
存储条件：

Pure form Sealed in dry,Room Temperature

In solvent -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 145 mg/mL(717.08 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
描述 MLR-1023 is a chemical compound which inhibits acid secretion in animal models and also acts as a bronchodilator in histamine-challenged animals.
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02317796 Type 2 Diabetes Phase 2 Completed - United States, Pennsylvania ... 展开 >> Melior Pharmaceuticals I & Bukwang Pharm. Co., Ltd. USA and South Korea, Pennsylvania, United States 收起 <<
NCT03279263 Type 2 Diabetes Mellitus Phase 2 Recruiting September 2019 United States, California ... 展开 >> National Research Institute Recruiting Los Angeles, California, United States, 90057 Contact: Juan Frias, MD 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

4.95mL

0.99mL

0.49mL

24.73mL

4.95mL

2.47mL

49.45mL

9.89mL

4.95mL
参考文献

[1]Saporito MS, Ochman AR, et al. MLR-1023 is a potent and selective allosteric activator of Lyn kinase in vitro that improves glucose tolerance in vivo. J Pharmacol Exp Ther. 2012 Jul;342(1):15-22.

[2]Ochman AR, Lipinski CA, et al. The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes. J Pharmacol Exp Ther. 2012 Jul;342(1):23-32.